SEC Form 4 · accession 0001209191-17-047139
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Jul 31, 2017
Accepted (ET)
Aug 2, 2017 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 31, 2017 | M | 11,063 | $45.11 | A | 268,455 | D | |
| Common StockF2,F3 | Jul 31, 2017 | S | 5,363 | $152.25 | D | 263,092 | D | |
| Common StockF3,F4 | Jul 31, 2017 | S | 5,000 | $153.24 | D | 258,092 | D | |
| Common StockF3,F5 | Jul 31, 2017 | S | 700 | $154.05 | D | 257,392 | D | |
| Common Stock | holding | — | — | — | 440 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $45.11 | Jul 31, 2017 | M | 11,063 | D | — | Feb 4, 2023 | Common Stock | 11,063 | 55,313 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $152.25 (range $151.79 to 152.77).
- F3Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $153.24 (range $152.79 to $153.78).
- F5Open market sales reported on this line occurred at a weighted average price of $154.05 (range $153.91 to $154.27).
- F6Fully vested.